

## TEER Guidance for New Centers

# Patient Selection for MitraClip : DMR and FMR

**Sung-Ji Park, MD, PhD**

Director of HVSI Imaging Center,  
Heart Vascular Stroke Institute,  
Samsung Medical Center,  
Sungkyunkwan University School of Medicine

# Outlines

- 1 Optimal candidate to TEER : Clinical perspectives**
- 2 Anatomically suitable MV anatomy for TEER**



# Outlines

**1 Optimal candidate to TEER : Clinical perspectives**

**2 Anatomically suitable MV anatomy for TEER**



# Current Guideline

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease



# Current Guideline

## 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease







# TEER Highlights from ACC/AHA VHD Guidelines

- **TEER for primary MR**
  - 2014 Class 2b → 2020 Class 2A
  - Recommendation of TEER expanded to include **surgical high-risk pts**
  - Condition for optimal GDMT for pts is removed
- **TEER for secondary MR**
  - New 2020 Class 2A
  - Recommended for a COAPT-like subsets for severe 2ndary MR pts
    - **20%<LVEF<50%, LVESD ≤ 70mm, PASP ≤ 70mmHg**
    - **Persistent symptoms while GDMT**
  - **Optimal GDMT by a cardiologist expert**

YES	COAPT criteria Indication CoR IIa LoE B for M-TEER in SMR	NO
<ul style="list-style-type: none"><li>- Severe SMR</li><li>- Optimised HF treatments according to 2021 ESC guidelines</li><li>- NYHA Class II, III or ambulatory IV</li><li>- LVEF 20-50%</li><li>- LV end-systolic diameter ≤70 mm</li><li>- At least one HF hospitalisation within the previous year or increased NP levels<sup>a</sup></li><li>- Anatomy judged suitable for M-TEER<sup>b</sup></li></ul>		<ul style="list-style-type: none"><li>- Haemodynamic instability<sup>c</sup></li><li>- Stage D HF<sup>d</sup></li><li>- Moderate or severe RV dysfunction</li><li>- Systolic pulmonary pressure &gt;70 mmHg</li><li>- COPD requiring oxygen or steroid</li><li>- Coronary, aortic or tricuspid valve disease requiring surgery</li><li>- Hypertrophic, restrictive or infiltrative cardiomyopathy</li></ul>



# FMR : Proportionate and Disproportionate MR

## MITRA-FR like subset Proportionate MR



LV 75.9/63.1 mm  
LVEF 29%  
ERO 0.57 cm<sup>2</sup>  
RV 55.8 ml

## COAPT like subset Disproportionate MR



LV 59.8/42 mm  
LVEF 49%  
ERO 0.33 cm<sup>2</sup>  
RV 51.2 ml

JAMA Cardiol. doi:10.1001/jamacardio.2019.5971



# Determinants of TEER efficacy in FMR

Optimal	Conditionally suitable	Unsuitable
NYHA class II-III	NYHA class IV	NYHA class IV, frequent HHF
Non-ischemic CMP	Ischemic CMP	ICMP with large infarct size (>30%)
Disproportionate MR EROA/LVEDV ratio $\geq 0.14$ LVEDV index $<96\text{mL/m}^2$	Proportionate MR	Advanced LV ds (pVO <sub>2</sub> $<10\text{ml/kg/min}$ ) EROA/LVEDV ratio $\leq 0.12$
Preserved RV function	RV dysfunction with CR	RV dysfunction without CR
No pulmonary hypertension	Reversible pul.HT	Irreversible pul.HT
ECV on cardiac MR $<30\%$	ECV on cardiac MR $>30\%$	NT proBNP $>10,000\text{ pg/mL}$

Adapted from Front. Cardiovasc. Med. 2021;8:585415



# Outlines


- 1 Optimal candidate to TEER : Clinical perspectives
- 2 Anatomically suitable MV anatomy for TEER
- 3 Assessment of TEER during procedure

# Suitable MV morphology for TEER

## 2020 Focused Update of 2017 ACC expert consensus decision pathway

**TABLE 7** Feasibility of Transcatheter Edge-to-Edge Clip Repair

	Favorable Features*	Less Favorable or Unfavorable Features*
Location of Leaflet Pathology	Noncommissural pathology (medial, middle, lateral segments)	Commissural segments, leaflet perforations, or clefts
Calcification	No or minimal calcification	<ul style="list-style-type: none"> <li>■ Severe leaflet calcification or calcification in area of grasping zone</li> <li>■ Severe annular calcification</li> </ul>
Mean MV Gradient	Transmitral gradient <4 mm	Mitral stenosis (rheumatic or calcific; mean mitral gradient >5 mm Hg)
MVA	MVA ≥4.0 cm <sup>2</sup>	MVA <4.0 cm <sup>2</sup>
Grasping Zone Length	>10 mm	<7 mm



MVA 5.46 cm<sup>2</sup>



P2 length= 1.30 cm

JACC 2020;75:2236-70

# Suitable MV morphology for TEER

## 2020 Focused Update of 2017 ACC expert consensus decision pathway

**TABLE 7** Feasibility of Transcatheter Edge-to-Edge Clip Repair

**Favorable Features\***

**Less Favorable or Unfavorable Features\***

**Primary MR**



Flail width <15 mm; flail gap <10 mm; single segment pathology Normal leaflet thickness

- Flail width >15 mm and flail gap >10 mm
- Multisegment pathology; highly mobile flail leaflet with multiple ruptured chords
- Severely and diffusely thickened (5 mm in diastole) and redundant leaflets (Barlow's type valve); LVESD >55 mm

**Secondary MR**

Coaptation depth <11 mm; coaptation length (overlap length) ≥2 mm

LVESD >70 mm



JACC 2020;75:2236-70

# Criteria for MV-TEER

## Complexity of valve morphology and center experience as criteria for MV-TEER

Repair!		Replacement?	
Anatomical suitability for M-TEER		Centre experience	
Non-complex Ideal for M-TEER	Complex Suitable for M-TEER	Very complex Challenging for M-TEER	Criteria favouring replacement M-TEER hard or impossible
<ul style="list-style-type: none"> <li>- Central pathology</li> <li>- No calcification</li> <li>- MVA &gt;4.0 cm<sup>2</sup></li> <li>- Posterior leaflet &gt;10 mm</li> <li>- Tenting height &lt;10 mm</li> <li>- Flail gap &lt;10 mm</li> <li>- Flail width &lt;15 mm</li> </ul>	<ul style="list-style-type: none"> <li>- Isolated commissural lesion (A1/P1 or A3/P3)</li> <li>- Annular calcification without leaflet involvement</li> <li>- MVA 3.5-4.0 cm<sup>2</sup></li> <li>- Posterior leaflet length 7-10 mm</li> <li>- Tenting height &gt;10 mm</li> <li>- Asymmetric tethering<sup>26</sup></li> <li>- Coaptation reserve &lt;3 mm<sup>24</sup></li> <li>- Leaflet-to-anulus index &lt;1.2<sup>25</sup></li> <li>- Flail width &gt;15 mm</li> <li>- Flail gap &gt;10 mm</li> <li>- Two jets from leaflet indentations</li> </ul>	<ul style="list-style-type: none"> <li>- Commissural lesion with multiple jets</li> <li>- Annular calcification with leaflet involvement</li> <li>- Fibrotic leaflets</li> <li>- Wide jet involving the whole coaptation</li> <li>- MVA 3.0-3.5 cm<sup>2</sup></li> <li>- Posterior leaflet length 5-7 mm</li> <li>- Barlow's disease</li> <li>- Cleft</li> <li>- Failed surgical annuloplasty</li> </ul>	<ul style="list-style-type: none"> <li>- Concentric MAC with stenosis</li> <li>- MVA &lt;3.0 cm<sup>2</sup></li> <li>- Relevant mitral valve stenosis (mean gradient &gt;5 mmHg)</li> <li>- Posterior leaflet &lt;5 mm</li> <li>- Calcification in the grasping zone</li> <li>- Deep regurgitant cleft</li> <li>- Leaflet perforation</li> <li>- Multiple/wide jets</li> <li>- Rheumatic mitral stenosis</li> </ul>



# Favorable MV morphology for TEER : DMR

## Primary MR


## 85/F Primary MR

**Repair!**

Anatomical suitability

**Non-complex  
Ideal for M-TEER**


- Central pathology
- No calcification
- MVA >4.0 cm<sup>2</sup>
- Posterior leaflet >10 mm
- Tenting height <10 mm
- Flail gap <10 mm
- Flail width <15 mm



# Favorable MV morphology for TEER : FMR

## Secondary MR

Coaptation depth <math>< 11\text{mm}</math>  
Coaptation length  $\geq 2\text{mm}</math>$






Coaptation depth : distance from the point of coaptation to the annular plane

Coaptation length : length of residual leaflet below the point of coaptation

JASE 2018;31:434-53

## 76/F HFrEF with severe Secondary MR

LV 75.9/63.1 mm, LVEF 29%








# Favorable MV morphology for TEER : FMR





76/F HFrEF with severe Secondary MR

LV 75.9/63.1 mm, LVEF 29%

## 1<sup>st</sup> MitraClip(XTW) implantation




## 2<sup>nd</sup> MitraClip(NTW) implantation





# Unfavorable MV morphology for TEER : DMR

81/M Primary MR, AF



**Primary MR**  
**Flail width <15mm**  
**Flail gap < 10mm**




**A 1 & A2 prolapse with chordae rupture**

**=> MVR & Maze OP**



# Less Favorable MV morphology for TEER : DMR

73/F Primary MR, ESRD on HD



**P1 prolapse with chordae rupture  
Leaflet thickening and chordae calcification**

### Less Favorable or Unfavorable Features\*

Commissural segments, leaflet perforations, or clefts




- Severe leaflet calcification or calcification in area of grasping zone
- Severe annular calcification



# Less Favorable MV morphology for TEER : DMR

## 73/F Primary MR, ESRD on HD





### 1<sup>st</sup> Clip (XT) 2<sup>nd</sup> Clip (XT)





# Less Favorable MV morphology for TEER


74/M Atrial MR, HCMP(1997 Dx), AF (1997 Dx)  
Rt. MCA Inf (2009 Dx)



LV 57.3/36.3 mm

EF 62%



LAVI=269.2 ml/m<sup>2</sup>





# Less Favorable MV morphology for TEER

74/M Atrial MR, HCMP(1997 Dx), AF (1997 Dx)





# Less Favorable MV morphology for TEER

74/M Atrial MR, HCMP(1997 Dx), AF (1997 Dx)  
Rt. MCA Inf (2009 Dx)

## Case : LJS

### Transthoracic Echocardiography

- Date : 2023-01-14
- Post. MV annulus calcification & slightly prolapsed AMVL with severe eccentric MR
  - MR PISA r= 0.92cm, MV ERO= 40.5mm<sup>2</sup>,
  - MR RV= 50.38ml, MR RV by vol= 45ml,
  - Pulmonic vein systolic reversal flow : (-)
- LV size : LVIDd = 57.3mm, LVIDs = 36.3mm
- LVEDV= 161.93ml, LVESV= 60.02ml)
- LVEF : 62.9%, LA : 85.5mm, LAVI : 262.9ml/m<sup>2</sup>
- RV systolic pressure : 45.7mmHg
- Aortic regurgitation : minimal
- Mitral regurgitation : moderate to severe
- Tricuspid regurgitation : mild


## Case : LJS

### Transesophageal Echocardiography

- Date : 2023-01-16
- 1) Severe MR with PMVL tethering (P2 portion)
  - Posterior annulus calcification, calcification on chorda
  - PISA radius= 1.06cm, MV meanPG= 2.8mmHg
  - Systolic reversal flow into LAA (+), left pulmonary vein (+)
- 12. MitraClip information
  - PMVL tethering (P2 portion)
  - Non-coaptation gap: max 0.4cm
  - PMVL length : 1.1~ 1.23cm
  - Septal puncture height : >4.5cm
  - MV area : 5.48cm<sup>2</sup>, 7.03cm<sup>2</sup> , meanPG : 2.8mmHg
  - Limitation : Huge LA, PFO

# Less Favorable MV morphology for TEER

74/M Atrial MR, HCMP(1997 Dx), AF (1997 Dx)



Atrial fMR

Huge enlarged LA (LAVI 262.9 ml/m<sup>2</sup>)

Multiple jets at A2/P2 (1.5, 2.5)

NonCoaptation gap 3~4mm

plan :

1st Clip with XTW at 1.5 area

2nd Clip with XTW at 2.5 area


Septal puncture; Inferior-posterior as much as possible







# Less Favorable MV morphology for TEER

## 74/M Atrial MR, HCMP(1997 Dx), AF (1997 Dx)



1<sup>st</sup> Clip (XTW) at 1.5 area











# Less Favorable MV morphology for TEER

## 74/M Atrial MR, HCMP(1997 Dx), AF (1997 Dx)

### 2<sup>nd</sup> Clip (XTW) at 2.5 area



1<sup>st</sup> Clip (XTW) at 1.5 area    2<sup>nd</sup> Clip (XTW) at 2.5 area



# Special Thanks to SMC SHD TEER team

## Imaging team



Sung-Ji Park



Eun Kyoung Kim



Jihoon Kim

## Intervention team




Joo Yong Hahn



Ki Hong Choi

## VHD surgery team



Kiick Sung



Dong-Seop Jeong



Suryeun Chung

## VHD Anesthesiology team



## Take Home Message

- **Selection of the optimal candidate for MitraClip is the best way to succeed in the procedure.**